Ampio Announces Accepted Publication of Pooled Ampion ™ Clinical Trial Results in Patients with Severe Osteoarthritis of the Knee

ENGLEWOOD, Colo., Oct. 12, 2017  -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced that a manuscript titled: "LMWF-5A For The Treatment Of Severe Osteoarthritis Of The Knee: Integrated Analysis Of Safety And Efficacy" was accepted for publication in Orthopedics, an international peer-reviewed journal in the field of Orthopedics. Ampion™ is the Low Molecular Weight Fraction of 5% human serum Albumin (LMWF-5A).
 
Ampio's Chief Scientific Officer, Dr. David Bar-Or described the study as follows: "This was a combined analysis of all completed single-injection Ampion™ randomized placebo-controlled trials to date, focusing on the subset of patients with severe (Kellgren-Lawrence [KL] grade 4) osteoarthritis of the knee (OAK). The objective of the study was to examine the safety and efficacy of an intra-articular injection of Ampion™ compared to a saline placebo control in patients with severe OAK. Safety and efficacy measurements, subject eligibility, treatment, randomization and blinding, were identical across all trials."
Published: 12 October 2017
Written by Editor
AMEX   Up on News   Project Update  
Read more: Ampio Pharmaceuticals ( AMPE )

Milestone Scientific Announces over 500 Successful Procedures Using CompuFlo(R) Epidural System

Zero Complications Reported
 
LIVINGSTON, NJ --(October 11, 2017) - Milestone Scientific Inc.(NYSE American: MLSS) (NYSE MKT: MLSS), a developer of painless and precise computerized drug delivery instruments, today announced that its CompuFlo® Epidural System has been successfully utilized in over 500 epidural procedures, including both labor and delivery, as well as pain management, with no complications reported. The CompuFlo® Epidural System has been deployed in a variety of settings at leading institutions in the U.S., Europe and South America.
 
Prof. Giorgio Capogna, Director of the European School of Obstetric Anesthesia and Head of the Department of Anesthesia at Città di Roma Hospital, commented, "Mastering the art of an epidural injection takes years of practice. Learning to use the CompuFlo® Epidural System was fast and simple. Given its ease-of-use and ability to precisely identify the epidural space, the CompuFlo® Epidural System should become the standard-of-care for epidural procedures."
Published: 11 October 2017
Written by Editor
AMEX   Up on News   Project Update  
Read more: Milestone Scientific Inc ( MLSS )

CEL-SCI Granted European Patent for Multikine ’s Mechanism of Action in Making Tumors ‘Visible ’ to the Immune System

2017-10-10 08:30 ET - VIENNA, Va. -- CEL-SCI Corporation (NYSE American:CVM) announced today that the European Patent Office has issued a new patent to CEL-SCI for its lead investigational immunotherapy, Multikine* (Leukocyte Interleukin, Injection), which is currently in a pivotal Phase 3 trial for head and neck cancer. Patent # EP 1 879 618 B1 is titled, “A Method for Modulating HLA Class II Tumor Cell Surface Expression With A Cytokine Mixture” addresses Multikine’s mechanism of action to make tumors more visible to the immune system.
 
“This is a key patent which along with the other Multikine issued patents addresses how Multikine enables the immune system to recognize and attack the tumor. One way tumor cells evade the immune system is by expressing human leukocyte antigens (HLA) on the tumor cell surface, thus appearing as ‘self’ to the immune cells and therefore the tumor cells are not attacked,” stated Eyal Talor, PhD, CEL-SCI’s Chief Scientific Officer.
Published: 10 October 2017
Written by Editor
AMEX   Up on News   Project Update  
Read more: CEL-SCI Corporation ( CVM )

AnaptysBio Reports Positive Topline Proof-of-Concept Data from Phase 2a Clinical Trial of ANB020 in Atopic Dermatitis

 83 Percent of Patients Achieved EASI-50 at Day 29 Following a Single Dose of ANB020
EASI-50 was Observed Early and Persisted Through Day 57
Management to Host Conference Call Today at 8:30 a.m. EDT
 
2017-10-10 06:30 ET - SAN DIEGO, Oct. 10, 2017  -- AnaptysBio, Inc. (Nasdaq:ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today announced positive proof-of-concept data for ANB020, its investigational anti-IL-33 therapeutic antibody, in an ongoing Phase 2a clinical trial in adult patients with moderate-to-severe atopic dermatitis. 
Published: 10 October 2017
Written by Editor
Nasdaq   Up on News   Project Update  
Read more: AnaptysBio Inc ( ANAB )

KalVista Pharmaceuticals Announces Collaboration with Merck

– Covers Development of Investigational Plasma Kallikrein Inhibitors for Treatment of Diabetic Macular Edema –
– $37 Million Upfront Fee Plus Potential Milestone Payments and Sales Royalties –
– Merck Acquires 9.9% Stake in KalVista in Private Placement –
– Investigational Intravitreal DME Candidate KVD001 Phase 2 Clinical Trial Still Planned to Initiate in 2017 –
 
2017-10-10 07:30 ET - CAMBRIDGE, Mass. - KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced that it has entered into a collaboration agreement with Merck, known as MSD outside the United States and Canada, through a subsidiary, for KVD001, the Company’s investigational intravitreal (IVT) injection candidate currently in development for potential treatment of diabetic macular edema (DME), as well as future oral DME compounds based upon plasma kallikrein inhibition.
Published: 10 October 2017
Written by Editor
Nasdaq   Up on News   Project Update  
Read more: KalVista Pharmaceuticals ( KALV )
  1. 22nd Century Group ( XXII )
  2. Zogenix Inc ( ZGNX )
  3. Spectrum Pharmaceuticals ( SPPI )
  4. Zynerba Pharmaceuticals ( ZYNE )
  5. ITUS Corporation ( ITUS )